Connect with us

Financing

Ocumetics Announces Advertising Campaign with Investing News Network

    

Calgary, Alberta – TheNewswire – March 3, 2023 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO)…

Published

on

    

Calgary, AlbertaTheNewswire – March 3, 2023 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) has retained Dig Media Inc. dba Investing News Network (“INN”) to assist in an advertising and investor awareness campaign.

 

INN is a private company headquartered in Vancouver, Canada, dedicated to providing independent news and education to investors since 2007. For the 12 month term of the agreement, INN will provide advertising to increase awareness of the Company. INN does not provide Investor Relations or Market Making services. The cost of the campaign is $54,900 payable in standard net 30 terms. INN is arm’s length to Ocumetics and holds no securities in Ocumetics.

 

About Ocumetics

 

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and development company that specializes in adaptive intraocular lens designs.  Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the capsular bag following extracapsular cataract extraction.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, potentially to eliminate the need for corrective lenses.

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dr. Mark Lee

President and CEO

(604) 832-6052

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the clinical trial program outlined above and that it will be conducted as expected.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Copyright (c) 2023 TheNewswire – All rights reserved.

financing
tsx
tsxv
tsx venture
venture exchange
otc
tsxv-otc
ocumetics-technology-corp
press-release

Financing

nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) Announces an Expansion of its YMI Validation Project

 

Calgary, Alberta – TheNewswire – October 17, 2023 – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) announces an expansion…

Continue Reading
Financing

NervGen Pharma Appoints John Ruffolo to Board of Directors

Extensive experience in private equity, venture capital and advising high growth, innovative companiesBrings personal experience and knowledge of spinal…

Continue Reading
Financing

Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma

Vancouver, British Columbia–(Newsfile Corp. – October 17, 2023) – Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical…

Continue Reading

Trending